Matthew A. Karlyn has 23 years of experience in working with companies in the healthcare, pharmaceutical, medical device, and technology industries on a wide range of commercial life sciences, licensing, and technology transactions. His clients range from Fortune 100 companies to start-ups, and he regularly advises companies on matters involving IP commercialization, complex collaboration transactions, licensing initiatives, subscription-based economics, and business transactions related to the procurement, development, commercialization, and use of technology and life sciences products. He has also worked with a number of clients on corporate transactions including mergers and acquisitions, as well as private equity and venture capital financing.

Life Sciences

Life sciences clients, including pharmaceutical, medical device, and healthcare companies, rely on Matt for his breadth of knowledge in licensing, collaboration, and commercialization strategies across a wide range of transactions designed to strengthen operations and maximize value. Matt’s clients come from sectors across the global economy and include emerging companies, privately held companies, and many of the world’s biggest brands.

Matt has broad experience with commercial transactions and agreements in the life sciences space, including:

  • Intellectual property and technology licenses
  • Collaboration and development transactions
  • Commercialization agreements
  • Supply and manufacturing transactions


Matt regularly advises on the use of technology in business, pricing strategies, and market terms across a wide variety of technology transactions that benefit clients both large and small. He has extensive experience negotiating a wide range of transactions, including:

  • Enterprise resource planning and customer relationship management licensing and implementation transactions
  • Cloud-based transactions including software-as-a-services, platform-as-a-service, and infrastructure-as-a-service.
  • Software licensing
  • Supply chain and procurement deals

Additionally, Matt has worked on many of the largest outsourcing transactions in the United States, representing numerous Fortune 100 companies on information technology, business process, finance and accounting, facilities services, and other outsourcing transactions.

Matt is a frequent author and speaker on topics pertaining to drafting and negotiating commercial technology, outsourcing, and licensing transactions. He has published over 25 articles (including chapters in two books), given over 175 presentations on licensing, technology, outsourcing, and data security, and is the co-author of A Guide to IT Contracting: Checklists, Tools, and Techniques.

Matt is currently co-chair of the Legal and Regulatory policy group at the Massachusetts Biotechnology Council. He served as chair of the New England Chapter of the International Association of Outsourcing Professionals, and served for five years on the board of directors of Julie’s Family Learning Program, a wellness program for mothers and children in South Boston.

Show More


  • Represented LIVEKINDLY Collective, a collection of heritage and start-up brands on track to become one of the world's largest plant-based food companies, on the commercial and intellectual property aspects of its establishment, together with RCL Foods, of a plant-based joint venture, LIVEKINDLY Collective Africa.

  • Represent Adagene, a clinical stage biotech company, in a material transfer and research relationship associated with Adagene’s proprietary materials, with a major university.

  • Represented Vizgen in a university licensing transaction to support Vizgen’s gene profiling instrumentation and data analysis, with a major university.

  • Represented CareDx, a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, in licensing and research collaboration agreements with a major university, and in a material transfer agreement to support a feasibility study with CRISPR Therapeutics.

  • Represented clients in licensing and other commercial life sciences transactions adverse to a number of universities including Harvard, MIT, Cornell, Stanford, University of California-San Diego, University of California-Berkeley, University of Pittsburgh, University of Michigan, Tufts, and Northeastern.

  • Represented BluesphereBio in all licensing matters, including pending deals with a major university and the university's medical center.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.